SuperworthCryo Cell International profit margin CCEL
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −6.2%
- Operating margin, 12 months
- 0.6%
- Net margin on a year earlier
- −4.8 pts
- Peer median
- 6.8%
Over the twelve months to Aug 31, 2026, Cryo Cell International kept −6.2% of its revenue as net profit, with an operating margin of 0.6% and a gross margin of 78.5%.
Five years earlier its net margin was 13.5%.
The median for 10 healthcare stocks of a similar size is 6.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −7.7% | 1.5% | 76.6% |
| FY2024 | 1.3% | 10.9% | 75.4% |
| FY2023 | −30.4% | −39.3% | 73.2% |
| FY2022 | 9.1% | 13.3% | 71.0% |
| FY2021 | 7.2% | 13.9% | 68.9% |
| FY2020 | 11.6% | 24.6% | 69.0% |
| FY2019 | 7.2% | 15.9% | 68.5% |
| FY2018 | −2.9% | 17.8% | 70.8% |
| FY2017 | 9.1% | 19.7% | 73.5% |
| FY2016 | −5.7% | 1.9% | 75.0% |
| FY2015 | 38.4% | 13.9% | 73.3% |
| FY2014 | 2.8% | 9.8% | 72.0% |
| FY2013 | 0.1% | 9.0% | 72.0% |
| FY2012 | −35.1% | −9.5% | 72.8% |
| FY2011 | −11.7% | −1.5% | 75.4% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q3 FY26 | −6.2% | −4.8 pts | 0.6% | |
| Q2 FY26 | −7.9% | −7.4 pts | −0.3% | |
| Q1 FY26 | −8.5% | −8.9 pts | 0.6% | |
| Q4 FY25 | −7.7% | −9.0 pts | 1.5% | |
| Q3 FY25 | −1.5% | +26.5 pts | 13.6% | |
| Q2 FY25 | −0.5% | +28.8 pts | 11.9% | |
| Q1 FY25 | 0.4% | +31.4 pts | 11.6% | |
| Q4 FY24 | 1.3% | +31.6 pts | 10.9% | |
| Q3 FY24 | −28.0% | −36.1 pts | −39.5% | |
| Q2 FY24 | −29.4% | −36.8 pts | −40.5% | |
| Q1 FY24 | −31.0% | −39.8 pts | −42.0% | |
| Q4 FY23 | −30.4% | −39.5 pts | −39.3% |
Against its peers
Companies in Healthcare nearest Cryo Cell International's size, closest first, today.
| Company | Profit margin |
|---|---|
| CCELCryo Cell International | −6.2% |
| NEPHNephros | 8.4% |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 6.8% |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| ICCCImmucell | 2.6% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| PLXProtalix BioTherapeutics | 23.5% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 6.8% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Cryo Cell International
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.